Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston blog main
clinical trials
drugs
4
×
life sciences
national blog main
rna interference
4
×
boston
boston top stories
aminolevulinic acid
biotech
fda
givosiran
new york blog main
new york top stories
patisiran
regeneron pharmaceuticals
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
alirocumab
amgen
barry greene
boston university
dan ollendorf
evercore isi
evolocumab
heart attack
hereditary transthyretin amyloidosis
inclisiran
inotersen
john berk
joseph swartz
mary o'donnell
medicines co.
national top stories
new york
onpattro
What
alnylam
rna
4
×
drug
medicine
pharmaceuticals
ago
data
fda
interference
new
rnai
second
seek
speedy
approval
approve
awaits
based
biological
cholesterol
cleared
crossed
decades
decision
discovered
evidence
far
fingers
friday
heart
historic
indicated
lasting
long
looms
lowering
market
medco
medicines
nasdaq
Language
Current search:
drugs
×
rna
×
" rna interference "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision